- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP — Recruiting • Phase III • NCT06920004.
- Trial comparing new drug empasiprubart against standard IVIg treatment for CIDP over 24 weeks, then all patients receive empasiprubart for 24 months.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy Interventions: empasiprubart, IVIg, empasiprubart-placebo,…